February 5, 2012

Baker’s Dozen Trying to Beat the Odds in Pancreatic Cancer

Pancreatic Cancer Image

November marks Pancreatic Cancer Awareness Month – a baker’s dozen are trying to beat the odds in treating the disease.

Past Pitfalls and Potential Promise for Pancreatic Cancer

pancreatic_slide

Next month [November] marks Pancreatic Cancer Awareness Month.  Visibility for the disease is already on the rise due to recent celebrity victims, including Apple’s Steve Jobs and Hollywood actor Patrick Swayze. According to the American Cancer Society, pancreatic cancer is a devastating disease with the worst mortality rate and an overall 5-year survival rate lower [...]

Investment Opportunities with Five Frontline Therapies for AML

473462-small

Acute myelogenous leukemia [AML] is a fast-growing cancer of the blood and bone marrow.  Unformed cells called myeloblasts, or “blasts,” reside in the bone marrow and normally become a particular kind of cell – a white blood cell, red blood cell, or platelet.  In AML, abnormal blasts produce white blood cells that do not function [...]

Monoclonal Antibody Companies Command Premiums

Monoclonal antibody image from MD Becker Partners

Monoclonal antibodies, which have been approved for immunological, anti-infective, ophthalmic, cancer and other categories, represent one of the most successful therapeutic drug classes.  Ten monoclonal antibodies have been approved for cancer therapy alone, including three blockbuster products sold by the Roche Group (RHHBY) – Avastin® [bevacizumab], Rituxan® [rituximab], and Herceptin® [trastuzumab] that collectively represented nearly [...]

Buyout Buzz at ASH Hematology Confab

473462-small

Scientific and medical advances weren’t the only topic of discussion at the 51st American Society of Hematology [ASH] Annual Meeting that began over the weekend in New Orleans, LA, as merger and acquisition activity took center stage. Early this morning, Celgene Corporation (CELG) announced the acquisition of privately-held Gloucester Pharmaceuticals for $340 million in cash [...]